×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Investors

2016 Annual Meeting of Stockholders

Amgen held its 2016 Annual Meeting of Stockholders on May 19, 2016, in Westlake Village, California. At this meeting, stockholders were asked to vote on various items as included in the Notice of 2016 Annual Meeting of Stockholders and Proxy Statement. Approximately 89 percent of outstanding shares were represented at the meeting.

The director nominees David Baltimore, Frank J. Biondi, Jr., Robert A. Bradway, François de Carbonnel, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Frank C. Herringer, Tyler Jacks, Judith C. Pelham, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen's Board of Directors. Each director received approximately 96 percent or more of the votes cast “For.” Also at the meeting, retiring director Vance D. Coffman was recognized for his contributions while on the Board. With the re-election of all of the director nominees and Dr. Coffman’s retirement, Amgen currently has 13 directors.

With approximately 98 percent of the votes cast “For,” stockholders ratified Ernst & Young LLP as Amgen's independent registered public accountants for the year ending December 31, 2016.

Stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, commonly known as “Say on Pay.” The non-binding proposal gives stockholders the opportunity to endorse or not endorse Amgen’s executive pay programs and policies. Say on Pay received approximately 97 percent of the votes cast “For” the proposal.

The stockholder proposal to change the voting standard applicable to non-binding proposals submitted by stockholders did not pass, receiving approximately 7 percent of the votes cast “For” the proposal.

Counting of Votes

All votes have been tabulated by the inspector of election appointed for the 2016 Annual Meeting of Stockholders. The inspector of election separately tabulated affirmative and negative votes and abstentions and broker “non-votes.” A broker non-vote occurs when a nominee holding shares for a beneficial owner has not received instructions from the beneficial owner and does not have discretionary authority to vote the shares.

With respect to the 2016 Annual Meeting of Stockholders:

  • Subject to Amgen’s Amended and Restated Bylaws the election of directors required a majority of the votes cast. Abstentions and broker non-votes had no effect in determining the election of directors.
  • The ratification of the selection of Ernst & Young LLP as our independent public accountants for the fiscal year ending December 31, 2016 required the affirmative vote of a majority of the shares present or represented by proxy at the 2016 Annual Meeting of Stockholders and entitled to vote on the matter. Abstentions had the same effect as votes against the ratification. There were no broker non-votes in connection with the ratification.
  • The approval of the advisory vote on our executive compensation required the affirmative vote of a majority of the shares present or represented by proxy at the 2016 Annual Meeting of Stockholders and entitled to vote on the matter. Abstentions had the same effect as votes against the proposal and broker non-votes had no effect on the proposal.
  • The approval of the stockholder proposal required the affirmative vote of a majority of the shares present or represented by proxy at the 2016 Annual Meeting of Stockholders and entitled to vote on the matter. Abstentions had the same effect as votes against the proposal and broker non-votes had no effect on the proposal. 

Proxy Materials

2015 Annual Report to Stockholders

2016 Proxy Statement